Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Y. Fred Yang"'
Autor:
Frédéric Jaisser, Xiaojuan Tan, Shuangshuang Chi, Jinrong Liu, Ping Wang, Mark Bush, Vincent Benn, Y. Fred Yang, Jay Zhang
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
The therapeutic indices (TIs) and efficacy of the non-steroidal mineralocorticoid receptor antagonist (MRA) KBP-5074 and steroidal MRA eplerenone were evaluated in a uninephrectomized Sprague Dawley rat model of aldosterone-mediated renal disease. In
Externí odkaz:
https://doaj.org/article/70307f2212d94cf0ada186684e06954e
Autor:
Pablo E. Pergola, Nam Vo, Tamar Doliashvili, Belkis Delgado, James McCabe, Y. Fred Yang, Diyan Genov, George L. Bakris, Bertram Pitt, Vincent Benn
Publikováno v:
Hypertension (Dallas, Tex. : 1979)
Supplemental Digital Content is available in the text.
In patients with resistant or poorly controlled hypertension and advanced chronic kidney disease, mineralocorticoid receptor antagonists are recommended; however, hyperkalemia limits their u
In patients with resistant or poorly controlled hypertension and advanced chronic kidney disease, mineralocorticoid receptor antagonists are recommended; however, hyperkalemia limits their u
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c0856db64f265df1ac64c3be6d71f25
https://doi.org/10.1161/hypertensionaha.121.17073
https://doi.org/10.1161/hypertensionaha.121.17073
Autor:
Jay Zhang, Vincent Benn, Mark Bush, Y. Fred Yang, Shuangshuang Chi, Ping Wang, Jinrong Liu, Xiaojuan Tan, Frederic Jaisser
Publikováno v:
Frontiers in Pharmacology
Frontiers in Pharmacology, Frontiers, 2021, 12, ⟨10.3389/fphar.2021.604928⟩
Frontiers in Pharmacology, Vol 12 (2021)
Frontiers in Pharmacology, Frontiers, 2021, 12, ⟨10.3389/fphar.2021.604928⟩
Frontiers in Pharmacology, Vol 12 (2021)
The therapeutic indices (TIs) and efficacy of the non-steroidal mineralocorticoid receptor antagonist (MRA) KBP-5074 and steroidal MRA eplerenone were evaluated in a uninephrectomized Sprague Dawley rat model of aldosterone-mediated renal disease. In
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c065ebc8bd5e1f1804a38449087fb2d
https://hal.sorbonne-universite.fr/hal-03285721/file/fphar-12-604928.pdf
https://hal.sorbonne-universite.fr/hal-03285721/file/fphar-12-604928.pdf
Publikováno v:
Hypertension (Dallas, Tex. : 1979). 76(1)
Spironolactone, a steroidal mineralocorticoid receptor antagonist, is recommended as add-on therapy for treatment-resistant/uncontrolled hypertension. However, caution is advised in patients with advanced chronic kidney disease (CKD) due to an increa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e430a0806d1b8f6fd0f2ac3996a41ef
https://pubmed.ncbi.nlm.nih.gov/32520623
https://pubmed.ncbi.nlm.nih.gov/32520623